Korro Bio Inc KRRO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-10-03 |
| Shares Out. | 14,420,000 |
| Website | korrobio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 49 |
| Net Income | -$19.6M |
| Free Cash Flow | -$70.6M |
| Total Assets | $183.6M |
| Total Liabilities | $64.0M |
| Equity | $119.6M |
About Korro Bio Inc
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Korro Bio Inc is a publicly traded company under the ticker symbol KRRO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)